Successful identification of culprit drugs of perioperative anaphylaxis by repeated skin testing after negative first skin tests in a patient with a long distant history of perioperative anaphylaxis

Wasurat Sungworna, Orathai Theankeaw, Aree Jameekornrak Taweechue, Chamard Wongsab, Torpong Thongngarm, Mongkhon Sompornrattanaphan

Adverse Drug Reaction (ADR) Unit, Pharmacy Department, Siriraj Hospital, Mahidol University, Bangkok, Thailand
Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

ARTICLE INFO

Keywords:
- Anaphylaxis
- Anesthesia
- Hypersensitivity reactions
- Intraoperative
- Perioperative

ABSTRACT

Background: Perioperative anaphylaxis is a severe immediate hypersensitivity reaction to drugs administered in immediate temporal association to surgical procedures. The European Academy of Allergy and Clinical Immunology recommends allergologic tests be performed within the golden period of between 1 and 4 months after the date of the event to avoid false negatives. Nonetheless, many obstacles prevent patients from receiving diagnostic tests within the recommended time frame.

Case presentation: A 39-year-old male with congenital glaucoma had a history of multiple episodes of perioperative anaphylaxis since the age of 1 year including generalized urticaria, bronchospasm, cyanosis, and hypotension. Because the sequence of events was unclear due to incomplete documentation of operations and the destruction of medical records, the allergists tested different perioperative drugs on the patient. Although the first test results were all negative, repeated tests at 6 weeks were positive for morphine and ketamine. We identified more than one causative drug at the second round of skin tests. Using recommended skin test concentrations, negative skin tests in 5 control subjects could support the validity of the second test. The patient underwent sinus surgery in the next 3 months after the second skin test using propofol, midazolam, sevoflurane, chlorhexidine, and cefazolin without any anaphylactic reactions.

Conclusions: Repeated skin tests after negative results of the first tests may identify the causative drugs, thus providing optimal patient safety, and should be considered under the physician’s discretion together with consideration of the severity of the allergic symptoms, time interval from last reactions, and the patient’s consent.

1. Introduction

Anaphylaxis is defined as an acute, potentially life-threatening systemic reaction with a wide range of clinical manifestations [1]. Perioperative anaphylaxis is the anaphylaxis associated with anesthesia. The reported incidence has ranged from 1:353–1:1860 procedures from the United Kingdom Sixth National Audit Project (NAP6) [2], 1:3180 from a French prospective study [3], and 1:1480 from a Spanish prospective study [4]. This condition is challenging as many drugs are administered simultaneously, resulting in difficulty to conclude the culprit drugs. Therefore, allergologic workups, including in vitro and in vivo tests, are important to identify culprit drugs and safe alternatives [5, 6].

Both European and American guidelines currently recommend using skin tests as the main diagnostic method for evaluating drug hypersensitivity reactions caused by any general medication [7]. The European Academy of Allergy and Clinical Immunology (EAACI) recommends allergologic tests be performed within the golden period of between 1 and 4 months after the date of the anaphylactic event to avoid false negatives [5, 8]. Nonetheless, many obstacles prevent patients from receiving diagnostic tests within the recommended time frame. Herein, we report a patient with a history of perioperative anaphylaxis 10 years prior to allergologic evaluation. There were two rounds of test, for which the second round was 6 weeks after the first. The first round of skin tests showed negative results, but the second round of tests repeated using the...
same drugs as the first were positive for ketamine and morphine, which were identified as the culprit drugs.

2. Case presentation

A 39-year-old male with congenital glaucoma, epilepsy, hypertension, dyslipidemia, and diabetes and without a history of atopic disease had a history of multiple eyes examinations under anesthesia since the age of 1 year. Nonetheless, most of the medical records were narrative notes, and some of the anesthetic and medication records could not be retrieved. As a result, the medication list might have been incomplete.

The patient's history relating to allergy is summarized in Table 1. He developed his first episode of anaphylaxis at the age of 11 years during trabeculectomy performed under general anesthesia (GA) with thiopental and succinylcholine at a local hospital. The event was documented as a shock of unknown etiology. The second and third episodes of anaphylaxis occurred at the ages of 13 and 14 years, both of which involved cyanosis and hypotension shortly after induction of anesthesia during the eye examination. Consequently, the local hospital referred the patient to an academic hospital and issued an adverse drug reaction (ADR) card stating a suspicion of thiopental and succinylcholine allergy by guessing.

During the ages of 15–28 years, he had multiple surgical operations at the same academic hospital to which he had been referred. All operative and anesthetic records had been previously destroyed due to the prolonged loss of contact for more than five years. The patient claimed that the hospital did not use thiopental and succinylcholine according to the ADR card registered by the first local hospital. Nevertheless, the patient still suffered from three more episodes of anaphylaxis. Therefore, in accordance with the ADR unit, an anesthesiologist at the academic hospital specified the patient could be allergic to morphine and thiopental in the ADR card using informed guesswork. Nevertheless, the patient had an eye enucleation operation under GA without morphine and thiopental at the age of 29 years and developed anaphylaxis. After that event, the patient and his relatives were very frightened and discouraged, and they refrained from coming to the hospital for 10 years. The latest ADR record described an allergy to all anesthetic drugs except for propofol, succinylcholine, midazolam, and sevoflurane.

Ten years later, the patient visited our university hospital with chronic nasal congestion and was consequently diagnosed with chronic rhinosinusitis (CRS). He had no peripheral eosinophilia (absolute eosinophil count 3.82 μg/L, latex-specific immunoglobulin E (IgE) was 0 KUA/L, and complement C4 (C4) levels were 20 and 24 mg/dL at 2 different timepoints (normal range, 15–45 mg/dL). Because the patient had had severe immediate reactions, and all the initial test results were negative, we scheduled the next round of testing 6 weeks later. The second round of skin tests was performed with the same drugs at the same concentrations as the first tests. IDTs were positive for ketamine at 1 and 0.1 mg/mL concentrations, and SPTs were positive for morphine at 1 mg/mL concentration (Table 2).

We recommended the patients avoid ketamine and morphine. Alternative drugs were those testing negative, including fentanyl, propofol, thiopental, etomidate, midazolam, succinylcholine, cisatracurium, atracurium, and rocuronium. The ADR card was updated accordingly. Nonetheless, close observation for allergic symptoms was advised in the case of future anesthetic procedures with these alternative drugs. The patient underwent sinus surgery in the next 3 months after the second skin test using propofol, midazolam, sevoflurane, chlorhexidine, and cefazolin without any anaphylactic reactions. For all of the case history, images, and data to be published, written and informed consent was obtained from the patient. The patient was informed that de-identified data would be used in the scientific research and publications.

3. Discussion and conclusion

To the best of our knowledge, this is the first case report to demonstrate the clinical benefit of repeated skin tests in a patient with a history of severe immediate allergic reactions to perioperative drugs. The utility of the repeated tests in yielding identifications of causative drugs was still evident even after 10 years had passed since the last anaphylaxis. Although the first test results were negative, the repeated tests at 6 weeks were positive for morphine and ketamine, confirmed by the negative skin test of the mentioned drugs in healthy controls. Furthermore, we identified more than one causative drug at the second round of skin tests. The identification of ketamine as a causative drug could be explained the patient’s history of anaphylaxis episodes after morphine had been avoided. The rationale of the positive conversion is most likely due to the ‘booster effect’ after the drug re-exposure from the first skin test, resulting in a positive second skin test. Although the patient was exposed the culprit that was eventually identified several times, the lack of drug exposure for a long period could

---

Table 1. Summary of the patient's allergic history prior to the most recent set of visits involving skin tests.

| Anaphylaxis episode | Age (years) | Drugs used during operation | Reactions |
|---------------------|------------|-----------------------------|----------|
| 1st                 | 11         | (At least) thiopental and succinylcholine | Bronchospasm, cyanosis, and hypotension |
| 2nd                 | 13         | (At least) thiopental and succinylcholine | Bronchospasm, cyanosis, and hypotension |
| 3rd                 | 14         | Premedication: chlorpheniramine, dexamethasone (At least) thiopental, succinylcholine, atracurium | Bronchospasm, prolonged cyanosis, and hypotension |
|                     |            | ADR card: avoid thiopental and succinylcholine |         |
| Multiple episodes   | 15–28      | Avoid thiopental and succinylcholine. Unknown definite medication used during operation | 3 episodes of anaphylaxis |
| 3 episodes of anaphylaxis |         | ADR card was revised to: avoid thiopental and morphine |         |
| Last episode        | 29         | Enucleation operation: unknown medications used | Generalized urticaria, bronchospasm, and hypotension |

Abbreviation: ADR, adverse drug reaction.
have resulted in a decrease of the drug-specific IgE below the threshold of skin test detection while drug-specific memory B cell may have still been present. This phenomenon has been reported in other drugs [9]. The waning of drug-specific IgE over time could explain the lower detection rate in cases with a long time interval between the last reaction to skin test [10, 11]. We are aware of the possibility of nonspecific irritation from both morphine and ketamine. Using recommended skin test concentrations [5, 12], negative skin tests in the control subjects in the present report could support the validity of the second test.

The 2019 EAACI guideline [5, 12] suggests a repeated test for drug-specific IgE levels at 4–6 weeks after negative initial testing, which is similar to other recommendations [13, 14, 15]. This suggestion is supported by reports on Hymenopteran envenomation and some drugs. A refractory period of up to 6 weeks was reported after Hymenopteran envenomation, and specific IgE might be depleted in the anaphylaxis if the tests are performed too early [16, 17]. Conversely, the waning of drug-specific IgE over time could explain the lower detection rate in cases with a long time interval between the last reaction to the skin test. Opstrup,

### Table 2. Summary of skin tests results.

| Drug name                  | Concentration | Skin prick test | Intradermal test |
|----------------------------|---------------|-----------------|------------------|
|                           |               | 1st test        | 2nd test         | 1st test        | 2nd test       |
| Negative control (NSS)     | 0.9% NaCl     | neg             | neg              | 0.9% NaCl       | neg            | neg            |
| Positive control (Histamine) | 10 mg/mL      | 5 × 5 mm        | 6 × 5 mm         | N/A             | N/A            |
| Succinylcholine (Suxamethonium®) | 10 mg/mL  | neg             | neg              | 0.1 mg/mL       | neg            | neg            |
| Atracurium (Tracrium®)     | 1 mg/mL       | neg             | neg              | 0.01 mg/mL      | neg            | neg            |
| Cisatracurium (Nimbex®)    | 2 mg/mL       | neg             | neg              | 0.02 mg/mL      | neg            | neg            |
| Rocuronium (Esmeron®)      | 10 mg/mL      | neg             | neg              | 0.05 mg/mL      | neg            | neg            |
| Etomidate (Lipuro®)        | 2 mg/mL       | neg             | neg              | 0.2 mg/mL       | neg            | neg            |
| Ketamine                   | 100 mg/mL     | neg             | neg              | 1 mg/mL         | neg            | pos            |
| Propofol                   | 10 mg/mL      | neg             | neg              | 1 mg/mL         | neg            | neg            |
| Thiopental                 | 25 mg/mL      | neg             | neg              | 2.5 mg/mL       | neg            | neg            |
| Morphine                   | 1 mg/mL       | neg             | neg              | 0.005 mg/mL     | pos            | pos            |
| Fentanyl                   | 0.05 mg/mL    | neg             | neg              | 0.005 mg/mL     | neg            | neg            |
| Midazolam                  | 5 mg/mL       | neg             | neg              | 0.05 mg/mL      | neg            | neg            |
| Chlorhexidine              | 5 mg/mL       | neg             | neg              | 0.002 mg/mL     | neg            | neg            |

Abbreviations: neg, negative skin test; pos, positive skin test; EAACI, European Academic of Allergy and Clinical Immunology; N/A, not applicable; NSS, normal saline solution; SPT, skin prick test; IDT, intradermal test.

Notes:-

- **Positive IDT to ketamine**: 3 × 3 mm to 7 × 7 mm (flare 32 × 32 mm).
- **Positive SPT to morphine**: 4 × 3 mm (flare 12 × 10 mm).
- **Positive IDT to morphine**: (0.005 mg/mL) 3 × 3 mm → 8 × 8 mm (flare 29 × 27 mm), IDT to morphine (0.001 mg/mL) 3 × 3 mm → 6 × 6 mm (flare 18 × 15 mm).

Figure 1. The first skin test results were all negative. Abbreviations: Atra, atracurium; CHX, chlorhexidine; Cis, cis-atracurium; Roc, rocuronium; Succinyl, succinylcholine.
et al. [18] suggested the optimal sampling time seems to be >1 month and <4 months because they found chlorhexidine-specific IgE declined over months/years. Similar phenomena were demonstrated in antibiotics [10] and iodinated radiocontrast [11]. These findings are supported by a multi-centered European radiocontrast study in which positive test results were more frequent in patients tested within 2–6 months than those tested earlier than 2 months or later than 6 months [11].

However, there has been no evidence that such repeated tests have any utility and clinical benefits before the present report, in which the final outcome was no perioperative drug reaction. Not only could a repeated testing procedure identify the causative drugs, but it could also prevent future severe reactions. Previous studies have found patients with negative first test results could develop an anaphylactic reaction during procedures, implying that their prior test results were false negatives [19, 20]. Moreover, there has been a report of fatal anaphylaxis from a second amoxicillin/clavulanic acid provocation after a prior negative provocation [21].

In the present report, allergists decided to retest and consequently discovered the culprit drugs, which were ketamine and morphine. On the other hand, if only the first test was performed, a recurrent anaphylaxis might have occurred had the patient gone on to surgery without the repeated tests. This would potentially have occurred because one of the identified culprit drugs, ketamine, would not yet have been identified. Therefore, this case report illustrates the substantial benefit of repeated skin tests to prevent future severe reactions and provide optimal patient safety.

In conclusion, repeated skin tests after negative results of the first tests may identify the causative drugs, providing optimal patient safety, and should be considered under the physician’s discretion together with consideration of the severity of the allergic symptoms, the time interval from last reactions, and the patient’s consent.

Declarations

Author contribution statement

All authors listed have significantly contributed to the investigation, development and writing of this article.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data availability statement

Data will be made available on request.

Declaration of interests statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

Acknowledgements

We thank Dr. Anthony Tan for editing the English language in the manuscript.

References

[1] M.S. Shaker, D.V. Wallace, D.B.K. Golden, J. Oppenheimer, J.A. Bernstein, R.L. Campbell, et al., Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis, J. Allergy Clin. Immunol. 145 (4) (2020) 1082–1123.
[2] L.C. Savic, V. Kaura, M. Yusaf, A.M. Hammond-Jones, R. Jackson, S. Howell, et al., Incidence of suspected perioperative anaphylaxis: a multicenter snapshot study, J. Allergy Clin. Immunol. Pract. 3 (3) (2015) 454–455 e1.
[3] J.M. Malinovsky, S. Decagny, F. Wessel, L. Guilloux, P.M. Mertes, Systematic follow-up increases incidence of anaphylaxis during adverse reactions in anesthetized patients, Acta Anaesthesiol. Scand. 52 (2) (2008) 175–181.
[4] T. Lobera, M.T. Audicana, M.D. Pozo, A. Blanco, E. Fernandez, P. Canada, et al., Study of hypersensitivity reactions and anaphylaxis during anesthesia in Spain, J. Investig. Allergol. Clin. Immunol. 18 (5) (2008) 350–356.
[5] L.H. Garvey, D.G. Ebo, P.M. Mertes, P. Dewachter, T. Garecz, P. Kopac, et al., An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions, Allergy 74 (10) (2019) 1872–1884.
[6] B.L.B. Melchiors, L.H. Garvey, Investigation of perioperative hypersensitivity reactions: an update, Curr. Opin. Allergy Clin. Immunol. 20 (4) (2020) 338–345.

[7] M.J. Torres, A. Romano, G. Celik, P. Demoly, D.A. Khan, E. Macy, et al., Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America, Clin. Transl. Allergy 7 (2017) 7.

[8] F. Soetens, M. Rose, M. Fisher, Timing of skin testing after a suspected anaphylactic reaction during anaesthesia, Acta Anaesthesiol. Scand. 56 (8) (2012) 1042–1046.

[9] M. Simpornrattanaphan, C. Wongsa, P. Kreetapirom, A.J. Taweechue, O. Theankeaw, T. Thongpgarm, Fatal anaphylaxis from a second amoxicillin/clavulanic acid provocation after a prior negative provocation, J. Allergy Clin. Immunol. Pract. 8 (2) (2020) 752–754.

[10] A. Romano, F. Gaeta, R.L. Valluzzi, A. Zaffiro, C. Caruso, D. Quarantino, Natural evolution of skin-test sensitivity in patients with IgE-mediated hypersensitivity to cephalosporins, Allergy 69 (6) (2014) 806–809.

[11] K. Brockow, A. Romano, W. Aberer, A.J. Bircher, A. Barbaud, P. Bonadonna, et al., Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study, Allergy 64 (2) (2009) 234–241.

[12] L.H. Garvey, D.G. Ebo, P.-M. Mertes, P. Dewachter, T. Garcez, P. Kopac, et al., An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions, Allergy 74 (10) (2019) 1872–1884.

[13] S.A. Mishah, M.T. Krishna, Peri-operative anaphylaxis-an investigational challenge, Front. Immunol. 10 (2019) 1117.

[14] A. Lafuente, G. Javaleyes, F. Berroa, M.J. Guikoetxea, R. Moncada, J.M. Nurse-Cordova, et al., Early skin testing is effective for diagnosis of hypersensitivity reactions occurring during anesthesia, Allergy 68 (6) (2013) 820–822.

[15] A.D. Broyles, A. Banerji, M. Castells, Practical guidance for the evaluation and management of drug hypersensitivity: general concepts, J. Allergy Clin. Immunol. Pract. 8 (9) (2020) S3–S15.

[16] A. Goldberg, R. Confino-Cohen, Timing of venom skin tests and IgE determinations after insect sting anaphylaxis, J. Allergy Clin. Immunol. 100 (2) (1997) 182–184.

[17] F. Rueff, K.C. Bergmann, K. Brockow, T. Fuchs, A. Grubl, K. Jung, et al., [Skin tests for diagnostics of allergic immediate-type reactions. Guideline of the German Society for Allergology and Clinical Immunology], Pneumologie 65 (8) (2011) 484–495.

[18] M.S. Opstrup, L.K. Poulsen, H.J. Malling, B.M. Jensen, L.H. Garvey, Dynamics of plasma levels of specific IgE in chlorhexidine allergic patients with and without accidental re-exposure, Clin. Exp. Allergy 46 (8) (2016) 1090–1098.

[19] M. Fisher, D. Merefield, B. Baldo, Failure to prevent an anaphylactic reaction to a second neuromuscular blocking drug during anaesthesia, Br. J. Anaesth. 82 5 (1999) 770–773.

[20] B.A. Fraser, J.A. Smart, Anaphylaxis to cisatracurium following negative skin testing, Anaesth. Intensive Care 33 (6) (2005) 816–819.

[21] M. Simpornrattanaphan, P. Kreetapirom, Y. Srinoulprasert, D. Kanistanon, A. Klinniyom, C. Wongsa, et al., Severe anaphylaxis after pelvic examination: a case report of dual latex and chlorhexidine allergies, Allergy Asthma Clin. Immunol. 15 (2019) 19.